Travere Therapeutics (NASDAQ:TVTX) Shares Down 5.4% After Insider Selling

Travere Therapeutics, Inc. (NASDAQ:TVTX) traded down 5.4% during trading on Thursday after an insider sold shares in the company. The stock traded as low as $38.12 and last traded at $38.7250. 376,772 shares traded hands during trading, a decline of 82% from the average session volume of 2,139,902 shares. The stock had previously closed at $40.95.

Specifically, CAO Sandra Calvin sold 21,977 shares of the company’s stock in a transaction that occurred on Tuesday, April 14th. The stock was sold at an average price of $41.07, for a total transaction of $902,595.39. Following the sale, the chief accounting officer directly owned 42,353 shares in the company, valued at $1,739,437.71. This represents a 34.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Roy D. Baynes sold 32,750 shares of the company’s stock in a transaction that occurred on Tuesday, April 14th. The shares were sold at an average price of $41.29, for a total value of $1,352,247.50. Following the sale, the director owned 37,500 shares in the company, valued at approximately $1,548,375. This trade represents a 46.62% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In other Travere Therapeutics news, Director Gary A. Lyons sold 8,000 shares of the company’s stock in a transaction that occurred on Tuesday, April 14th. The stock was sold at an average price of $41.07, for a total transaction of $328,560.00. Following the sale, the director directly owned 57,500 shares in the company, valued at $2,361,525. This represents a 12.21% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Analysts Set New Price Targets

Several brokerages have recently weighed in on TVTX. Wedbush increased their target price on shares of Travere Therapeutics from $39.00 to $44.00 and gave the company an “outperform” rating in a research note on Tuesday. JPMorgan Chase & Co. lowered their target price on shares of Travere Therapeutics from $44.00 to $41.00 and set an “overweight” rating for the company in a report on Wednesday, March 25th. Weiss Ratings restated a “sell (e+)” rating on shares of Travere Therapeutics in a report on Wednesday, January 21st. Citigroup raised their target price on shares of Travere Therapeutics from $48.00 to $53.00 and gave the stock a “buy” rating in a report on Tuesday. Finally, Guggenheim raised their target price on shares of Travere Therapeutics from $49.00 to $54.00 and gave the stock a “buy” rating in a report on Tuesday. Eleven equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Travere Therapeutics has an average rating of “Moderate Buy” and an average price target of $42.50.

Travere Therapeutics News Summary

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: FDA grants full approval for Filspari in FSGS, materially expanding Travere’s rare‑kidney franchise and adding an estimated ~30,000 U.S. patients to the addressable market — the core reason for the earlier, large share price gain. Filspari approval article
• Positive Sentiment: Market reaction and analyst upgrades lifted sentiment and targets (examples: Canaccord, Guggenheim, Piper Sandler, HC Wainwright), reinforcing a re‑rating narrative and supporting higher medium‑term revenue expectations for Filspari. Guggenheim note
• Neutral Sentiment: Trading activity is elevated and options volumes spiked around the approval — this amplifies short‑term moves (both up and down) and suggests greater volatility while the market digests label details and early commercialization assumptions. Options activity report
• Neutral Sentiment: Company commentary and coverage (conference/transcript writeups, health press) are clarifying the label and launch plans, but concrete revenue/volume reads are not yet available — useful for modeling but not definitive. Company discussion
• Negative Sentiment: Multiple insiders (CEO, directors, CFO, other executives) sold material blocks of shares over the last two trading days — most sales were executed under pre‑arranged Rule 10b5‑1 plans or to cover taxes related to vesting, but the scale of selling can fuel near‑term downward pressure and signal profit‑taking after the approval‑driven rally. Example SEC filing for CEO sale. CEO Form 4
• Negative Sentiment: Some analysts warn that estimate‑revision trends and elevated expectations could limit near‑term upside — the stock may consolidate or pull back as investors re‑rate forward revenue assumptions. Zacks caution

Travere Therapeutics Price Performance

The company has a current ratio of 2.74, a quick ratio of 2.70 and a debt-to-equity ratio of 2.71. The stock has a market capitalization of $3.65 billion, a P/E ratio of -131.80 and a beta of 0.86. The stock has a 50 day moving average of $29.77 and a 200-day moving average of $31.42.

Institutional Investors Weigh In On Travere Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of TVTX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Travere Therapeutics by 13.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 56,777 shares of the company’s stock worth $1,029,000 after acquiring an additional 6,831 shares during the last quarter. Norges Bank bought a new stake in shares of Travere Therapeutics during the 2nd quarter worth approximately $1,051,000. First Trust Advisors LP bought a new stake in shares of Travere Therapeutics during the 2nd quarter worth approximately $3,538,000. Cresset Asset Management LLC lifted its stake in shares of Travere Therapeutics by 26.5% during the 2nd quarter. Cresset Asset Management LLC now owns 28,875 shares of the company’s stock worth $427,000 after acquiring an additional 6,047 shares during the last quarter. Finally, Qube Research & Technologies Ltd lifted its stake in shares of Travere Therapeutics by 106.2% during the 2nd quarter. Qube Research & Technologies Ltd now owns 604,128 shares of the company’s stock worth $8,941,000 after acquiring an additional 311,137 shares during the last quarter.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.